Why Pfizer (PFE) is on investors’ radar today

Pfizer (PFE) is back in focus after recent trading left the stock around $26.48. This has prompted investors to reassess how its current valuation lines up with its large global biopharma portfolio and earnings profile.

Recent trading has been slightly soft, with a 30 day share price return of 2.29% and a 90 day share price return of 2.72%. However, the 1 year total shareholder return of 25.69% points to stronger momentum over a longer window.

If this kind of large cap healthcare story has your attention, it can be useful to see what else is setting up interesting risk reward profiles across the sector via 35 healthcare AI stocks

With Pfizer delivering a 25.69% 1-year total return but carrying weaker recent momentum and an intrinsic value estimate implying a large discount, the key question is whether this represents genuine undervaluation or a market already pricing in future growth.

Most Popular Narrative: 13.5% Undervalued

According to the most followed narrative, Pfizer’s fair value sits at $30.62 versus the recent $26.48 share price, which frames the stock as discounted and raises questions about what assumptions drive that gap.

I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines. This should keep revenue flat, possibly growing in low to mid single digits in an optimistic scenario. Also, I think they will continue to release many new products that are already in phase 3 of research. If they're able to do this, maintain a 70% operational margin, increase profitability (by cutting costs, expanding margins etc.) and paying down debt, in the long term i see good anual returns (low double digits) from current stock price levels. There is risk for investors in the meantime! Pfizers transition needs to happen fast otherwise Pfizer will have to borrow more money due to the capital nature of the bussiness. Of course, this is not a capital light industry and pfizer debt levels are allready very high when we compare them with free cash flow to equity. Also, there is a risk of a dividend cut wich would harm investors. Investors should be aware of these risks in this turnaround play.

Want to see what keeps that $30.62 fair value in play according to Francisco? The heart of this narrative is oncology growth, a detailed revenue path and a tight margin and debt playbook that all have to line up.

Result: Fair Value of $30.62 (UNDERVALUED)

However, this hinges on execution. Slower oncology uptake, pressure on margins, or higher debt levels could quickly challenge the idea that Pfizer is meaningfully undervalued.

Next Steps

With that balance of risks and rewards in mind, do not wait on others to decide what it all means. Review the data and weigh the 1 key reward and 4 important warning signs.

Looking for more investment ideas?

If Pfizer has caught your attention, do not stop there. Widen your watchlist with other stocks that might fit your income, value, or quality goals.

Use the Simply Wall Street Screener to actively scan for fresh ideas that match your style so you are not relying on headlines or chance.

• Target reliable income streams by focusing on companies identified as potential 12 dividend fortresses that may suit investors who prioritize cash returns.
• Spot potential value opportunities before the crowd by reviewing companies highlighted in the 51 high quality undervalued stocks that align with your risk tolerance.
• Prioritize capital protection by concentrating on stocks surfaced in the 72 resilient stocks with low risk scores that may offer more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.